DOCSLIB.ORG

Challenge for COVID-19 Vaccines to Protect the New Zealand Population

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Challenge for COVID-19 Vaccines to Protect the New Zealand Population Te ara tika o te hauora hapori Journal of the New Zealand Medical Association Vol 134 | No 1534 | 30 April 2021 Challenge for COVID-19 vaccines to protect the New Zealand population Making the Convention on the Rights of Persons with Disabilities real: our word is our bond Why is it so hard for general practice to provide COVID-19 vaccines? Parental use of physical What does abortion law Predictors of medicinal cannabis users’ punishment in a birth reform mean for primary care willingness to utilise a new prescription cohort practitioners in New Zealand? Medicinal Cannabis Scheme in New Zealand Te ara tika o te hauora hapori Publication Information published by the New Zealand Medical Association NZMJ Editor NZMA Chair Professor Frank Frizelle Dr Kate Baddock NZMJ Production Editor NZMA Communications Manager Richard Beer Madeleine Boles de Boers (Acting) Other enquiries to: To contribute to the NZMJ, first read: NZMA www.nzma.org.nz/journal/contribute PO Box 156 The Terrace © NZMA 2021 Wellington 6140 Phone: (04) 472 4741 Cover photo courtesy of the Ministry of Health To subscribe to the NZMJ, email [email protected] Subscription to the New Zealand Medical Journal is free and automatic to NZMA members. Private subscription is available to institutions, to people who are not medical practitioners, and to medical practitioners who live outside New Zealand. Subscription rates are below. All access to the NZMJ is by login and password, but IP access is available to some subscribers. Read our Conditions of access for subscribers for further information www.nzma.org.nz/journal/subscribe/conditions-of-access If you are a member or a subscriber and have not yet received your login and password, or wish to receive email alerts, please email: [email protected] The NZMA also publishes the NZMJ Digest. This online magazine is sent out to members and subscribers six times a year and contains selected material from the NZMJ, along with all obituaries, summaries of all articles, and other NZMA and health sector news and information. Subscription rates for 2021 New Zealand subscription rates Overseas subscription rates Individuals* $349 Individual $486 Institutions $604 Institutions $650 Individual article $33 Individual article $33 *NZ individual subscribers must not be doctors (access is via NZMA Membership) New Zealand rates include GST. No GST is included in international rates. Note, subscription for part of a year is available at pro rata rates. Please email [email protected] for more information. Individual articles are available for purchase by emailing [email protected] NZMJ 30 April 2021, Vol 134 No 1534 ISSN 1175-8716 © NZMA 2 www.nzma.org.nz/journal CONTENTS EDITORIALS 66 8 Predictors of medicinal cannabis Making the Convention on the users’ willingness to utilise a new Rights of Persons with Disabilities prescription medicinal cannabis real: our word is our bond scheme in New Zealand James Cooney, Michael Daly, Marta Rychert, Chris Wilkins, Karl Parker, Giles Newton-Howes, Kris Gledhill, Thomas Graydon-Guy Sarah Gordon REVIEW ARTICLES 11 Challenge for COVID-19 76 vaccines to protect the Methoxyflurane toxicity: New Zealand population historical determination and Stephen T Chambers, Nigel J Raymond lessons for modern patient and occupational exposure ARTICLES Serah J Allison, Paul D Docherty, 17 Dirk Pons, J Geoffrey Chase Parental use of physical VIEWPOINTS punishment in a birth cohort Geraldine FH McLeod, John Horwood, 91 Joseph M Boden, Lianne J Woodward What does abortion law reform mean for primary care 31 practitioners in New Zealand? Demographic differences in Emma Macfarlane, Michael Stitely, the initiation and maintenance Helen Paterson of statins in the first year post ACS in New Zealand: a data linkage 99 Official Information study (ANZACS-QI 57) Aravindra Muniandy, Mildred Lee, Act investigation of the Ministry Corina Grey, Katherine Ferrier, of Health’s process to assess Andrew J Kerr the Southern District Health Board’s readiness to join the 46 National Bowel Screening The outcomes of patients Programme in 2018 with newly diagnosed exudative Philip Bagshaw, Paula Goodman, age-related macular degeneration Brian Cox in Palmerston North Aaron Yap, Adeline Kho, John Ah-Chan 114 Why is it so hard for 51 general practice to provide Comparison of physical-activity COVID-19 vaccines? patterns across large, Vanessa Weenink medium and small urban areas and rural settings in the Otago Region, New Zealand Brittany White, Enrique García Bengoechea, John C Spence, Kirsten J Coppell, Sandra Mandic NZMJ 30 April 2021, Vol 134 No 1534 ISSN 1175-8716 © NZMA 3 www.nzma.org.nz/journal contents CLINICAL CORRESPONDENCE LETTERS 118 146 Intravenous iron infusion and Letter to the editor newer non-dextran formulations Katherine Rich Tim Aung, Justin Coleman, Peter W Davidson, David J Hetzel, 148 Sandy T Aung Letter to the editor: response to Katherine Rich 128 Jennie Connor Granular parakeratosis secondary to benzalkonium OBITUARIES chloride exposure from common 150 household laundry rinse aids Dr William Alexander Fraser Catherine JL Tian, Diana Purvis, Harriet S Cheng 100 YEARS AGO 143 152 Cerebrospinal fluid rhinorrhoea Treatment of Mental following nasal packing for and Nervous Disorders epistaxis: case series from 1921 a single centre Alice Flavell-Birch, Campbell Baguley, Alice Stringer NZMJ 30 April 2021, Vol 134 No 1534 ISSN 1175-8716 © NZMA 4 www.nzma.org.nz/journal suMMaries Parental use of physical punishment in a birth cohort Geraldine FH McLeod, John Horwood, Joseph M Boden, Lianne J Woodward In 2007, as part of wider initiatives to improve child health outcomes, the New Zealand Government introduced important anti-smacking legislation that prohibited the use of physical punishment with children. This analysis examines the extent to which the preva- lence of child physical punishment by New Zealand parents may have changed over a 15-year period (2002–2017) spanning before and after this legislation. Findings showed a clear downward trend in the use of child physical punishment, with minor assaults reduced by almost a half (77% to 42%), and severe assaults by two-thirds (12% to 4%), between 2002 and 2017. Parents who were more likely to use physical punishment tended to be younger, caring for more children and in a violent partner relationship. A history of personal mental health problems and concurrent family socioeconomic disadvantage were also influential. Demographic differences in the initiation and maintenance of statins in the first year post ACS in New Zealand: a data linkage study (ANZACS-QI 57) Aravindra Muniandy, Mildred Lee, Corina Grey, Katherine Ferrier, Andrew J Kerr This study captured virtually all New Zealand patients discharged from hospital after a heart attack or unstable angina who had been considered appropriate for invasive heart treat- ments. A key pillar of management for these patients is ongoing cholesterol lowering with statin medication. We found that in the year after discharge only 60% of people received an optimal supply of daily statin medication. Māori and Pacific people were less likely to receive optimal medication than other ethnic groups. Suboptimal statin medication provision is likely to be a marker of less optimal medical management and of other healthcare more generally. We discuss the opportunities, both in hospital and in the community, to improve survival and quality of life by improving the use of these evidence-based prevention medications. The outcomes of patients with newly diagnosed exudative age-related macular degeneration in Palmerston North Aaron Yap, Adeline Kho, John Ah-Chan The Palmerston North Eye Department has employed innovative strategies to effectively treat the growing number of patients with wet macular degeneration. The information systems in place provide insight into the time it takes for patients with newly diagnosed wet macular degeneration to access sight-preserving treatment and their visual outcome. So far, it has shown that a good proportion of patients experience stabilisation and improvement of their vision on treatment. Furthermore, the time to access treatment has decreased over the past two years. NZMJ 30 April 2021, Vol 134 No 1534 ISSN 1175-8716 © NZMA 5 www.nzma.org.nz/journal suMMaries Comparison of physical-activity patterns across large, medium and small urban areas and rural settings in the Otago Region, New Zealand Brittany White, Enrique García Bengoechea, John C Spence, Kirsten J Coppell, Sandra Mandic Less than half of Otago adolescents meet physical-activity guidelines. Higher proportion of males, those participating in school sports and using active transport to school met physi- cal-activity guidelines compared to their counterparts. Overall, adolescents are less physically active on weekends compared to school days. Adolescents from large urban areas spent more time being stationary compared to their rural peers. Continuous encouragement of physical is needed for adolescents across urban and rural settings. Predictors of medicinal cannabis users’ willingness to utilise a new prescription medicinal cannabis scheme in New Zealand Marta Rychert, Chris Wilkins, Karl Parker, Thomas Graydon-Guy The online research survey of 3,634 medicinal cannabis users found majority (66%) were interested in transitioning to the new prescription Medicinal Cannabis Scheme (yet to be fully implemented). Medicinal-cannabis users with higher incomes, who are younger and who administered cannabis via smoking were more likely to express intention to use
Load more

Recommended publications
  • Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®)
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) Policy Number: 2021D0088F Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ....................................................................... 1 • Intravenous Iron Replacement Therapy (Feraheme®, Definitions ...................................................................................... 3 Injectafer®, & Monoferric®) Applicable Codes .......................................................................... 3 Background.................................................................................... 4 Benefit Considerations .................................................................. 4 Clinical Evidence ........................................................................... 5 U.S. Food and Drug Administration ............................................. 7 Centers for Medicare and Medicaid Services ............................. 8 References ..................................................................................... 8 Policy History/Revision Information ............................................. 9 Instructions for Use ....................................................................... 9 Coverage Rationale See Benefit Considerations This policy refers to the following intravenous iron replacements: Feraheme® (ferumoxytol) Injectafer® (ferric carboxymaltose) Monoferric® (ferric derisomaltose)* The following
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Medical Synagis (CPT) [RSV-Igim], for Intramuscular Use, 50 (PA) Mg, Each)
    CCHP Code Brand Name Description (PA) = Prior Authorization required Benefit Notes palivizumab (respiratory syncytial virus 90378 immune globulin Medical Synagis (CPT) [RSV-IgIM], for intramuscular use, 50 (PA) mg, each) lutetium lu 177, dotatate, therapeutic, Medical A9513 Lutathera 1 millicureie (PA) Medical A9590 Azedra Iodine I-131, iobenguane, 1 millicurie (PA) radium ra-223 dichloride, therapeutic, Medical A9606 Xofigo per microcurie (PA) in-line cartridge digestive enzyme for B4105 Relizorb Medical enteral feeding each COCAINE HCI NASAL SOL TOP ADMN 1 C9046 Goprelto Medical MG Medical C9047 Cablivi Injection, caplacizumab-yhdp, 1 mg (PA) Injection, romidepsin, non-lyophilized C9065 Medical (e.g. liquid), 1mg injection, belantamab mafodontin- C9069 Blenrep Medical blmf, 0.5 mg C9070 Monjuvi injection, tafasitamab-cxix, 2 mg Medical Medical C9071 Viltepso Injection, viltolarsen, 10 mg (PA) injection, immune globulin (asceniv), Medical C9072 Asceniv 500 mg (PA) Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car Medical C9073 Tecartus positive viable t cells, including (PA) leukapheresis and dose preparation procedures, per therapeutic dose Effective April 1, 2021 1 CCHP Code Brand Name Description (PA) = Prior Authorization required Benefit Notes prothrombin complex concentrate C9132 Kcentra (human), kcentra, per i.u. of factor ix Medical activity C9248 Cleviprex injection, clevidipine butyrate Medical C9250 Artiss artiss fibrin sealant Medical C9290 Exparel injection, bupivacaine liposome, 1 mg Medical C9293 Voraxaze
    [Show full text]
  • Healthy U Medical Pharmacy Prior Authorization List
    Below is the list of Medical Drug J-codes that require pre-service review for Healthy U. Please submit requests using the Medical Prior Auth Medical Electronic Request Form (select Medical Pharmacy from the drop down) or the PDF form that are available under Prior Authorization Forms, attach all necessary clinical documentation and submit to the Pharmacy Team by either fax to 801-213-1547 or by email: [email protected] If you have questions or need assistance regarding medical pharmacy please call for 833-981-0212 For questions regarding retail pharmacy please call RealRx pharmacy customer service: 855-856-5694 Procedure Code Description Portal Status 90378 RESPIRATORY SYNCYTIAL VIRUS IG IM 50 MG EA Not Covered 90626 TICK-BORNE ENCEPHALITIS VIRUS VACCINE, INACTIVATED; Not Covered 0.25 ML DOSAGE, FOR INTRAMUSCULAR USE 90627 TICK-BORNE ENCEPHALITIS VIRUS VACCINE, INACTIVATED; Not Covered 0.5 ML DOSAGE, FOR INTRAMUSCULAR USE 90671 PNEUMOCOCCAL CONJUGATE VACCINE, 15 VALENT Auth Required (PCV15), FOR INTRAMUSCUALR USE 90677 PNEUMOCOCCAL CONJUGATE VACCINE, 20 VALENT Auth Required (PCV20), FOR INTRAMUSCUALR USE 90758 ZAIRE EBOLAVIRUS VACCINE, LIVE, FOR INTRAMUSCUALR Not Covered USE 99601 HOME INFUSION/VISIT, 2 HRS Auth Required 99602 HOME INFUSION, EACH ADDTL HR Auth Required 0537T CAR-T THERAPY HRVG BLD DRV T LMPHCYT PR DAY Not Covered 0538T CAR-T THERAPY PREP BLOOD DERIVED T LMPHCYT FOR Not Covered TRANSPORTATION 0539T CAR-T THERAPY RECEIPT & PREP CAR-T CELLS FOR ADMIN Not Covered 0540T CAR-T THERAPY AUTOLOGOUS CELL ADMINISTRATION Not Covered A9276 DISPOSABLE SENSOR, CGM SYS Auth Required A9277 EXTERNAL TRANSMITTER, CGM Auth Required A9278 EXTERNAL RECEIVER, CGM SYS Auth Required A9513 LUTETIUM LU 177, DOTATATE, THERAPEUTIC, 1 MILLICURIE Auth Required 1 This Medical Pharmacy code list is updated regularly, and the Health Plan reserves the right to amend these policies and give notice in accordance with State and Federal requirements.
    [Show full text]
  • The Following Are J Code Requirements
    Updated The following are J Code requirements September 2021 J Codes Auth Required? 20610 - Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) No A9513 - Lutetium Lu 177, dotatate, therapeutic, 1 mCi Yes A9579 - Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (NOS), per ml No C9036 - Injection, patisiran, 0.1 mg Yes C9062 - Injection, daratumumab 10 mg and hyaluronidase-fihj Yes C9064 - Mitomycin pyelocalyceal instillation, 1 mg Yes C9065 - Injection, romidepsin, non-lypohilized (e.g. liquid), 1mg Yes C9066 - Injection, sacituzumab govitecan-hziy, 10 mg Yes C9069 - Injection, belantamab mafodontin-blmf, 0.5 mg Yes C9070 - Injection, tafasitamab-cxix, 2 mg Yes C9071 - Injection, viltolarsen, 10 mg Yes C9072 - Injection, immune globulin (asceniv), 500 mg Yes C9073 - Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Yes C9074 - Injection, lumasiran, 0.5 mg Yes J0129 - Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician) Yes J0131 - Injection, Acetaminophen, 10 mg No J0133 - Injection, acyclovir, 5 mg No J0150 - Injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use A9270) No J0171 - Injection, Adrenalin, epinephrine, 0.1 mg No J0178 - Injection, aflibercept, 1 mg No J0485 - Injection,
    [Show full text]
  • Injectable Medication Hcpcs/Dofr Crosswalk
    INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK HCPCS DRUG NAME GENERIC NAME PRIMARY CATEGORY SECONDARY CATEGORY J0287 ABELCET Amphotericin B lipid complex THERAPEUTIC INJ HOME HEALTH/INFUSION** J0400 ABILIFY Aripiprazole, intramuscular, 0.25 mg THERAPEUTIC INJ J0401 ABILIFY MAINTENA Apriprazole 300mg, IM injection THERAPEUTIC INJ J9264 ABRAXANE Paclitaxel protein-bound particles, 1 mg THERAPEUTIC INJ CHEMOTHERAPY* J1120 ACETAZOLAMIDE SODIUM Acetazolamide sodium injection THERAPEUTIC INJ J0132 ACETYLCYSTEINE INJ Acetylcysteine injection, 10 mg THERAPEUTIC INJ ACTEMRA 162mg/0.9ml Syringe (50242- J3262 Tocilizumab, 1 mg SELF-INJECTABLE 0138-01) ACTEMRA INJECTION (50242-0136- J3262 Tocilizumab 200mg, 400mg THERAPEUTIC INJ HOME HEALTH/INFUSION** 01, 50242-0137-01) J0800 ACTHAR HP Corticotropin injection THERAPEUTIC INJ Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4- 90648 ACTHIB THERAPEUTIC INJ IMMUNIZATIONS dose schedule), for intramuscular use J0795 ACTHREL Corticorelin Ovine Triflutal THERAPEUTIC INJ J9216 ACTIMMUNE Interferon gamma 1-b 3 miillion units SELF-INJECTABLE CHEMO ADJUNCT* J2997 ACTIVASE Alteplase recombinant, 1mg THERAPEUTIC INJ HOME HEALTH/INFUSION** J0133 ACYCLOVIR SODIUM Acyclovir, 5 mg THERAPEUTIC INJ HOME HEALTH/INFUSION** 90715 ADACEL Tdap vaccine, > 7 yrs, IM THERAPEUTIC INJ IMMUNIZATIONS J2504 ADAGEN Pegademase bovine, 25 IU THERAPEUTIC INJ HOME HEALTH/INFUSION** J0791 ADAKVEO Crizanlizumab-tmca IV Solution THERAPEUTIC INJ HOME HEALTH/INFUSION** J9042 ADCETRIS Brentuximab vedotin Injection THERAPEUTIC INJ CHEMOTHERAPY*
    [Show full text]
  • Ferric Derisomaltose (Monoferric)
    Clinical Policy: Ferric Derisomaltose (Monoferric) Reference Number: CP.PHAR.480 Effective Date: 06.01.20 Last Review Date: 05.21 Coding Implications Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Ferric derisomaltose (Monoferric™) injection is an iron replacement product. FDA Approved Indication(s) Monoferric is indicated for treatment of iron deficiency anemia (IDA) in adult patients: Who have intolerance to oral iron or have had unsatisfactory response to oral iron Who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). Policy/Criteria Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Monoferric is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Iron Deficiency Anemia with Chronic Kidney Disease (must meet all): 1. Diagnosis of IDA and CKD; 2. IDA is confirmed by either of the following: a. Transferrin saturation (TSAT) ≤ 30%; b. Serum ferritin ≤ 500 ng/mL; 3. If CKD does not require hemodialysis or peritoneal dialysis, oral iron therapy is not optimal due to any of the following: a. TSAT < 12%; b. Hgb < 7 g/dL; c. Symptomatic anemia; d. Severe or ongoing blood loss; e. Oral iron intolerance; f. Unable to achieve therapeutic targets with oral iron; g. Co-existing condition that may be refractory to oral iron therapy; 4. Dose does not exceed 1000 mg elemental iron (10 mL) per infusion/injection.
    [Show full text]
  • Evolving Evidence-Based Treatment Guidelines for Iron Deficiency Anemia in Inflammatory Bowel Disease: Considerations in Managed Care
    ® SUPPLEMENT July 2021 THE AMERICAN JOURNAL OF MANAGED CARE® Vol. 27 • No. 11, Sup. Evolving Evidence-Based Treatment Guidelines for Iron Deficiency Anemia in Inflammatory Bowel Disease: Considerations in Managed Care HIGHLIGHTS › Diagnosis and Management of Iron Deficiency Anemia in Inflammatory Bowel Disease › Impact of Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease: Considerations in Managed Care › CE Sample Posttest Supplement to The American Journal of Managed Care® © 2021 Managed Care & Healthcare Communications, LLC Evolving Evidence-Based Treatment Guidelines for Iron Deficiency Anemia in Inflammatory Bowel Disease: Considerations in Managed Care Release date: July 15, 2021 Educational Objectives Expiration date: July 15, 2022 Upon completion of this activity, participants should be able to: • Examine the biologic pathways relevant to iron hemostasis in inflamma- Estimated time to complete activity: 2 hours tory bowel disease (IBD) as well as appropriate monitoring of iron status. Type of activity: Application • Compare iron replacement therapies, including risks and benefits, for the Medium: Print with internet-based posttest, evaluation, and request for treatment of patients with IBD and iron deficiency. credit • Explore the health-related quality of life and economic burden of iron Fee: Free deficiency anemia in relation to the evolving evidence-based treatment protocols for patients with IBD and iron deficiency to improve outcomes This activity is supported by an educational grant from American Regent. and efficiently allocate healthcare resources. Intended Audience Accreditation Statement Pharmacists and managed care professionals Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Activity Overview provider of continuing pharmacy education. This activity is Iron deficiency anemia (IDA) is closely linked to inflammatory bowel approved for 2.0 contact hours (0.20 CEU) under the ACPE universal disease (IBD).
    [Show full text]
  • Extract from the Clinical Evaluation Report for [...]
    AusPAR Attachment 2 Extract from the Clinical Evaluation Report for Ferric derisomaltose Proprietary Product Name: Monofer Sponsor: Link Medical Products Pty Ltd T/A Link Pharmaceuticals First round report: 20 January 2017 Second round report: 23 June 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Healthours, and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About the Extract from the Clinical Evaluation Report • This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. • The words [Information redacted], where they appear in this document, indicate that confidential information has been deleted. • For the most recent Product Information (PI), please refer to the TGA website <https://www.tga.gov.au/product-information-pi>.
    [Show full text]
  • Iron Deficiency Without Anaemia: a Diagnosis That Matters
    Clinical Medicine 2021 Vol 21, No 2: 107–13 REVIEW Iron deficiency without anaemia: a diagnosis that matters Authors: Abdulrahman Al-Naseem,A Abdelrahman Sallam,A Shamim ChoudhuryA and Jecko ThachilB Iron deficiency anaemia (IDA) currently affects 1.2 billion females.3 Nevertheless, symptoms of anaemia such as fatigue people and iron deficiency without anaemia (IDWA) is at least can be present without anaemic haemoglobin levels.4 Recognising twice as common. IDWA is poorly recognised by clinicians IDWA as a clinical diagnosis is crucial to ensuring adequate despite its high prevalence, probably because of suboptimal management, especially for patients with chronic conditions such screening recommendations. Diagnosing IDWA relies on a as heart failure (HF) where IDWA can increase long-term mortality.5 ABSTRACT combination of tests, including haemoglobin and ferritin levels, as well as transferrin saturation. Although the causes Diagnostic definition of iron deficiency of iron deficiency may sometimes be obvious, many tend to be overlooked. Iron sufficiency throughout pregnancy Ferritin is an indicator of iron stores and is the most sensitive and is necessary for maternal and foetal health. Preoperative specific biomarker for assessing ID. The WHO defines low ferritin IDWA must be corrected to reduce the risk of transfusion and as levels <15 µg/L for adults and <12 µg/L for children.6 However, postoperative anaemia. Oral iron is the first-line treatment in clinical practice, when ferritin levels dip below 30 µg/L, ID can be for managing IDWA; however, intravenous supplementation ascertained.7 Ferritin is an acute-phase reactant that is increased should be used in chronic inflammatory conditions and when in serum during chronic inflammation.
    [Show full text]
  • North Carolina Division of Health Benefits Physician Administered Drug Program Catalog
    North Carolina Division of Health Benefits Physician Administered Drug Program Catalog North Carolina Division of Health Benefits Physician Administered Drug Program Catalog •Unless otherwise indicated, the catalog contains procedure codes representing drugs, biologics, devices and vaccines which are only covered for FDA approved indications. Covered indications that are not FDA approved are identified with **. •11 digit National Drug Codes (NDCs) are required to be billed along with their corresponding procedure code. Drugs and biologics must be classified as CMS covered outpatient drugs from a labeler/manufacturer participating in the Medicaid Drug Rebate Program (MDRP). •The Max Daily Units for radiopharmaceuticals represents one therapeutic dose or diagnostic dose. •The HCPCS Code effective date represents the date the HCPCS code was established •Procedure codes for covered devices and vaccines are not required to be from a rebating labeler/manufacturer as they are not classified as covered outpatient drugs. HCPCS HCPCS HCPCS Code Billing FDA Approved Indications Max Monthly Gender NDC Rebating Labeler Last Modified Category HCPCS Description Effective Brand Name Generic Name Max Daily Units Minimum Age Maximum Age Comments Code Unit (See Package Insert for full FDA approved indication descriptions) Units Restrictions Required Required Date Date Injection, amphotericin B lipid amphotericin B lipid complex Drugs J0287 10 mg 1/1/2003 Abelcet® Indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. 70 2,170 N/A N/A N/A Y Y 5/6/2019 complex, 10 mg injection aripiprazole extended-release Injection, aripiprazole, Indicated for the treatment of schizophrenia in adults.
    [Show full text]
  • Authorization Requirements for Medications Under the Medical Benefit
    Authorization Requirements for Medications Under the Medical Benefit HCPC/MOD OH MCD BRAND NAME LONG DESCRIPTION SHORT DESCRIPTION Limits 90375 No Auth. Required HyperRab Rabies Immune Globulin (Human) Rabies Immune Globulin (Human) 90378 Auth Required Synagis Palivizumab Synagis Up to 5 treatments Imovax Rabies vaccine, for intramuscular use (Code 90675 No Auth. Required Rabies vaccine, for intramuscular use Rabavert price is per 1 mL) Maximum 2 units 91300 No Auth. Required Pfizer COVID-19 Vaccine SARSCOV2 VAC 30MCG/0.3ML IM Pfizer-Biontech Covid-19 Vaccine Must be billed with 0001A or 0002A Maximum 2 units 91301 No Auth. Required Moderna COVID-19 Vaccine SARSCOV2 VAC 100MCG/0.5ML IM Moderna Covid-19 Vaccine Must be billed with 0011A or 0012A Postpartum Maternal Newborn Assessment Postpartum Maternal Newborn 4 Units Within 180 99501 No Auth. Required Service Assessment Service days 4 Units Within 180 99502 No Auth. Required Newborn Assessment Newborn Assessment days Home Nursing Visit for Medication Home Nursing Visit for Medication 99506 Auth Required Administration Administration 17Alpha-hydroxyprogesterone Caproate (17P) 17Alpha-hydroxyprogesterone Caproate 99600 No Auth. Required Administration Nursing Service (17P) Administration Nursing Service Home infusion/specialty drug administration, Home infusion/specialty drug 99601 No Auth. Required Up to 2 hours per day per visit (up to 2 hours) administration, per visit (up to 2 hours) Home infusion/specialty drug Home infusion/specialty drug administration, administration, per visit (up to 2 hours); per visit (up to 2 hours); each additional hour each additional hour (List separately in 99602 No Auth. Required (List separately in addition to code 99601 for Up to 2 hours per day addition to code 99601 for primary primary procedure) (Use 99602 in conjunction procedure) (Use 99602 in conjunction with 99601) with 99601) Maximum 1 per each Pfizer COVID-19 Vaccine Pfizer-Biontech Covid-19 Vaccine 0001A No Auth.
    [Show full text]